>If the pain reduction results are good but do not stack up against pregabalin (the latter has more pain free days in prior trials) then how would it fare in the marketplace?<
DEPO can try competing against Lyrica on price since Lyrica is one of those drugs where managed care likes to argue that the performance does not justify the cost premium relative to generic gabapentin. Gabapentin ER might be able to find a sweet spot in between Lyrica and the generic. However, I don’t really know much about this market and I’m just speculating.
Market Data 
Markets 
AI
